Proteome-wide mendelian randomization identifies FCRL3 and LY9 as potential therapeutic targets for lymphoma
Our study identified 37 potential lymphoma drug targets, emphasizing FCRL3 and LY9 as valuable therapeutic candidates, and amiodarone and chrysin in clinical translational application.
Authors
- Shunfeng Hu (ORCID: https://orcid.org/0000-0002-6893-7065)
- Juanjuan Shang (ORCID: https://orcid.org/0009-0005-9586-9650)
- Yingshu Luo
- Xin Wang (ORCID: https://orcid.org/0000-0001-5032-5290)
- Han Yang (ORCID: https://orcid.org/0000-0002-8791-3616)
- Bingyu Liu (ORCID: https://orcid.org/0000-0003-4817-5355)
- Qianqian Guo (ORCID: https://orcid.org/0000-0003-2912-486X)
- Mei Ding (ORCID: https://orcid.org/0000-0002-7210-7283)
Institutions
- Shandong University (CN)
- Shandong Provincial Hospital (CN)
- Taishan University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1007/s12672-025-03931-z
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Postdoctoral Science Foundation
- Natural Science Foundation of Shandong Province
- Shandong First Medical University
- Key Technology Research and Development Program of Shandong